Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 128 от 154

Активно (без набиране) Фаза 3

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Breast Neoplasms

The safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's choice of chemotherapy in the treatment of chemotherapy-candidate hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally recurrent inoperable or metastatic breast cancer. The primary hypotheses are that the combination of pembrolizumab and chemotherapy is superior to placebo and chemotherapy in regards to Progression-Free Survival (PFS) in participants with programmed cell death-ligand 1 (PD-L1) combined positive score (CPS) ≥1. Prior to protocol amendment 7, participants who discontinued pembrolizumab/placebo with SD or better and subsequently experienced disease progression may have been eligible for up to 17 additional administrations of pembrolizumab if, upon unblinding, they were found to have received pembrolizumab, at the same dose and schedule used for the initial treatment period.

Начало: 18.06.2021 Край: 18.12.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +26 Merck Sharp & Dohme LLC NCT04895358

Активно (без набиране) Фаза 3

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

Arthritis, Psoriatic

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.

Начало: 17.06.2021 Край: 05.10.2027 Възраст: от 18 г. Лечение

Australia, Bosnia and Herzegovina, Bulgaria +25 Janssen Research & Development, LLC NCT04882098

Активно (без набиране) Фаза 2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis

Myelofibrosis

This study is an open label, phase IIa trial in subjects with Myelofibrosis

Начало: 09.06.2021 Край: 30.06.2026 Възраст: от 18 г. Лечение

Australia, Germany, Italy +1 Galecto Biotech AB NCT04679870

Активно (без набиране) Фаза 3

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Non-small Cell Lung Cancer NSCLC

The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with PD-L1 high, locally advanced/recurrent or untreated metastatic NSCLC.

Начало: 08.06.2021 Край: 31.03.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +16 BeiGene NCT04746924

Активно (без набиране) Фаза 2

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Relapsed/Refractory Peripheral T-Cell Lymphoma Adult T Cell Leukemia/Lymphoma

This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma.

Начало: 03.06.2021 Край: 19.02.2027 Възраст: от 18 г. Лечение

Australia, Canada, France +9 Daiichi Sankyo NCT04703192

Активно (без набиране) Фаза 2

Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA

Advanced Prostate Carcinoma Cancer of Prostate PSA Castrate Resistant Prostate Cancer

Darolutamide is a drug that has a proven survival benefit in non-metastatic (M0) castrate resistant prostate cancer when using conventional imaging. However, it is estimated that \>90% of patients have disease apparent when using PSMA PET. This study investigates the use of local consolidation radiotherapy in this cohort of men.

Начало: 02.06.2021 Край: 01.06.2026 Възраст: от 18 г. Лечение

Australia, Singapore Trans Tasman Radiation Oncology Group NCT04319783

Активно (без набиране) Фаза 2

Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)

Non-small Cell Lung Cancer

Tomivosertib combined with pembrolizumab in Subjects with PD-L1 positive NSCLC

Начало: 02.06.2021 Край: 09.12.2024 Възраст: от 18 г. Лечение

Australia, Georgia, United States Effector Therapeutics NCT04622007

Активно (без набиране) Фаза 3

A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)

Alexander Disease

The purpose of this study is to evaluate the safety and efficacy of zilganersen (ION373) in improving or stabilizing gross motor function across the full range of affected domains in patients with AxD.

Начало: 01.06.2021 Край: 01.09.2029 Възраст: 2–65 г. Лечение

Australia, Canada, Israel +5 Ionis Pharmaceuticals, Inc. NCT04849741

Активно (без набиране) Фаза 3

RegoNivo vs Standard of Care Chemotherapy in AGOC

Gastro-Oesophageal Cancer

To determine if the regorafenib and nivolumab combination (RegoNivo) improves overall survival compared with current standard chemotherapy options in refractory AGOC.

Начало: 01.06.2021 Край: 01.06.2026 Възраст: от 18 г. Лечение

Australia, Germany, Italy +5 Australasian Gastro-Intestinal Trials Group NCT04879368

Активно (без набиране)

Breast Fractionation Study - Standard Versus Investigational Fractionation Trial - Nodal Radiation

Breast Cancer Post Mastectomy

The purpose of this study is to investigate the difference in fatigue, quality of life and radiation morbidity between hypofractionated and conventional radiation to the breast, chest wall and regional lymph nodes post mastectomy or lumpectomy

Начало: 01.06.2021 Край: 31.12.2027 Възраст: от 18 г. Лечение

Australia Royal North Shore Hospital NCT04909125

Активно (без набиране)

STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation

Atrial Fibrillation

The objective of this study is to compare the efficacy of three different ablation strategies in patients with persistent AF: 1. PV antral isolation alone (PVAI) 2. PV antral isolation plus ablation of drivers (PVAI+drivers) 3. PV antral isolation plus isolation of posterior wall (PVAI+box) All three strategies will employ contemporary catheter ablation technology using more efficient open irrigated tip cooling and contact force sensing.

Начало: 01.06.2021 Край: 01.12.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +5 McGill University Health Centre/Research Institute of t NCT04428944

Активно (без набиране) Фаза 2

A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)

Atrial Fibrillation

This Phase 2 study is a two-stage, serial cohort dose escalation and expansion study of a single 30-minute (IV) infusion of HBI-3000 for the conversion of patients with recent-onset atrial fibrillation (AF). Stage A is open label and all patients will receive HBI-3000. In each of three dose cohorts, up to 10 patients will receive HBI-3000 by IV infusion (30 minutes). Three different dose levels are planned to be administered serially, lowest to highest, with assessment of safety, tolerability, and efficacy prior to proceeding to the next dose level group. Following Stage A, the iDMC will recommend up to two doses of HBI-3000 to be further explored in Stage B. Stage B is a serial, randomized, double-blind and placebo-controlled cohort of two different doses of HBI-3000, with a dose decision after the first cohort. Stage B will be powered to show a difference between HBI-3000 and placebo in conversion rate at each of the two dose levels.

Начало: 01.06.2021 Край: 31.12.2025 Възраст: 18–80 г. Лечение

Bosnia and Herzegovina, Canada, New Zealand +2 HUYABIO International, LLC. NCT04680026

Активно (без набиране)

A Clinical Study on Implants With TiUltra Technology and Associated Prosthetic Components

Marginal Bone Level Change

This is a multicenter, prospective, non-interventional study in which a total of 1000 subjects in need of a single, multiple or full arch restoration in any region of the mouth (healed or extracted) will be treated in up to 30 study centers. The primary aim of this study is to demonstrate non-inferiority of all NobelBiocare TiUltra implants to historic data from NobelActive TiUnite coated implant in terms of marginal bone level change over 5 years after final prosthetic delivery. Eligible subjects who provide their informed consent for participation will be enrolled into one of four groups, each sized to 250 individuals. They will be treated with the corresponding implant system assigned to the group. The allocation into a certain group is only driven by the subject's clinical and restorative requirement and standard of care at the enrolling study clinic. Each subject will be followed for 5 years after definitive prosthetic placement

Начало: 26.05.2021 Край: 31.05.2029 Възраст: 18–65 г.

Australia, Denmark, Finland +8 Nobel Biocare NCT04737421

Активно (без набиране) Фаза 3

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on participants who have active disease and are already taking standard of care medications. These may include antimalarials, steroids, and immunosuppressants. The main objective of the study is to learn about the effect litifilimab has on lowering the activity of the disease. The main question researchers want to answer is: \- How many participants have an improvement in their symptoms after 52 weeks of treatment? Researchers will answer this and other questions by measuring the symptoms of SLE over time using a variety of scoring tools. These include the SLE Responder Index (SRI), the Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K), the British Isles Lupus Activity Group-2004 index (BILAG-2004), and the BILAG-BASED Combined Lupus Assessment (BICLA), among others. Researchers will also learn more about the safety of litifilimab. They will study how participants' immune systems respond to litifilimab. Additionally, they will measure the effect litifilimab and SLE have on the quality of life of participants using a group of questionnaires. The study will be done as follows: * After screening, participants will be randomized to receive either a high or low dose of litifilimab, or placebo. A placebo looks like the study drug but contains no real medicine. * All participants will receive either litifilimab or placebo as injections under the skin once every 4 weeks. The treatment period will last 52 weeks. Participants will continue to take their standard of care medications. * Neither the researchers nor the participants will know if the participants are receiving litifilimab or placebo. * There will be a follow-up safety period that lasts up to 24 weeks. * In total, participants will have up to 22 study visits. The total study duration for participants will be up to 80 weeks.

Начало: 25.05.2021 Край: 16.03.2027 Възраст: от 18 г. Лечение

Australia, Brazil, Bulgaria +12 Biogen NCT04895241

Активно (без набиране) Фаза 3

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

Clear Cell Renal Cell Carcinoma

The purpose of this study is to evaluate the drug levels, efficacy, safety, and tolerability of subcutaneous nivolumab versus intravenous nivolumab in participants with previously treated clear cell renal cell carcinoma that is advanced or has spread. The purpose of this study's substudy is to evaluate drug level biocomparability of subcutaneous nivolumab manufactured using two different manufacturing processes.

Начало: 21.05.2021 Край: 10.05.2027 Възраст: от 18 г. Лечение

Argentina, Brazil, Chile +13 Bristol-Myers Squibb NCT04810078

Активно (без набиране) Фаза 3

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Autoimmune Pulmonary Alveolar Proteinosis

160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim (MOL) or placebo (PBO) for 48 weeks. Subjects completing the 48-week placebo-controlled period will receive open-label treatment with once daily inhaled molgramostim for 96 weeks.

Начало: 19.05.2021 Край: 30.05.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +14 Savara Inc. NCT04544293

Активно (без набиране) Фаза 3

A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation

The primary objective of this study is to evaluate the efficacy of tofersen in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to evaluate the safety and tolerability tofersen and to evaluate the effect of tofersen on pharmacodynamics (PD)/treatment response biomarkers when initiated prior to versus at the time of emergence of clinically manifest amyotrophic lateral sclerosis (ALS).

Начало: 17.05.2021 Край: 30.04.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +11 Biogen NCT04856982

Активно (без набиране) Фаза 1

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

Melanoma

This study will evaluate the safety, pharmacokinetics, and activity of belvarafenib as a single agent and in combination with either cobimetinib or cobimetinib plus nivolumab in patients with NRAS-mutant advanced melanoma who have received anti-PD-1/PD-L1 therapy.

Начало: 13.05.2021 Край: 30.06.2027 Възраст: от 18 г. Лечение

Australia, Canada, Germany +2 Genentech, Inc. NCT04835805

Активно (без набиране) Фаза 3

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Prostate Cancer

The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR-deficient mCSPC.

Начало: 12.05.2021 Край: 28.08.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +24 Pfizer NCT04821622

Активно (без набиране) Фаза 3

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

Diffuse Large B-cell Lymphoma

This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed DLBCL

Начало: 11.05.2021 Край: 01.11.2027 Възраст: 18–80 г. Лечение

Argentina, Australia, Canada +25 Incyte Corporation NCT04824092

1 … 126 127 128 129 130 … 154